Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-arm study of KJ103 desensitization in highly sensitized kidney transplant patients
CTR20252973Phase 3Active
- Sponsor
- Shanghai Baoji Pharmaceutical
- Start
- Aug 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ricefidase in allosensitization in kidney transplantation, HLA antibody positivity, sponsored by Shanghai Baoji Pharmaceutical. Started Aug 2025; status: active.
02
Drugs
ricefidase
03
Conditions
allosensitization in kidney transplantationHLA antibody positivity
Beyond the preview
Go deeper on CTR20252973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252973.